Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients

Leukemia Research

Volumn 32, Issue 2, 2008, Pages 251-254

  Zheng, Wen Li ^a   Zhang, Guang Sen ^a   Xu, Yun Xiao ^a   Shen, Jian Kai ^a   Dai, Chong Wen ^a   Pei, Min Fei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Arsenic trioxide; Higher risk MDS; Retinoid acid; Thalidomide

Indexed keywords

ARSENIC TRIOXIDE; RETINOIC ACID; THALIDOMIDE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRY LIP; FLUID RETENTION; HEADACHE; HUMAN; LIP DISEASE; LIVER DYSFUNCTION; MYELODYSPLASTIC SYNDROME; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OXIDES; RISK FACTORS; THALIDOMIDE; TREATMENT OUTCOME; TRETINOIN;

EID: 38949162576     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.05.025     Document Type: Article

References (8)

1. Greenberg P., Cox C., and LeBeau M.M. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
2. Faderl S., and Kantarjian H.M. Novel therapies for myelodysplastic syndromes. Cancer 101 2 (2004) 226-241
3. Raza A., Buonamici S., Lisak L., Tahir S., Li D., Imran M., et al. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 8 (2004 Aug 28) 791-803
4. Bennett J.M., Catovsky D., and Daniel M.T. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
5. WHO. A handbook for reporting results of cancer treatment (1979), WHO Publications, Geneva
6. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. World Health Organization (WHO) International Working Group, Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96(12),3671-4.
7. Soignet S.L., Maslak P., and Wang Z.G. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339 19 (1998) 1314-1318
8. Rajkumar S.V., Haymen S., and Fonseca R. Thalidomide plus dexamethasone and thalidomide alone as first-line therapy for newly diagnosed myeloma. Blood 96 Suppl 1 (2000) 168a